$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer

2014-08

2015-04

2015-04

3

Study Overview

(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer

This Phase Ib dose escalation study will evaluate BTH1704, a monoclonal antibody that targets an aberrantly glycosylated antigen Mucin 1, and Imprime PGG, a glucan contained in yeast that is essential in triggering a leukocyte-mediated cytotoxic response towards tumor cells, in combination with gemcitabine in patients with advanced PDAC. The three intravenous drugs are taken in tandem 4 times in a 28-day cycle. The MAD of BTH1704 (BTH, 3 dose levels) in combination with gemcitabine (Gem) and Imprime PGG (I) will be determined using a standard ȣ+3" design. Treatment continues until disease progression, unacceptable toxicity, physician discretion, or patient refusal.

N/A

  • Pancreatic Cancer
  • DRUG: BTH1704
  • DRUG: IMPRIME PGG
  • DRUG: Gemcitabine
  • 2013-1115

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2014-05-05  

N/A  

2015-04-29  

2014-05-05  

N/A  

2015-05-01  

2014-05-07  

N/A  

2015-04  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: IMPRIME PGG, BTH1704, & Gemcitabine

Imprime PGG with BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day cycle with Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day cycle.

DRUG: BTH1704

  • BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.

DRUG: IMPRIME PGG

  • Imprime PGG at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.

DRUG: Gemcitabine

  • Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day (4 week) cycle.
Primary Outcome MeasuresMeasure DescriptionTime Frame
Maximum Tolerated Dose (MTD)The primary objective of this Phase 1b study is to determine the maximal administered dose (MAD) of BTH1704 (Mucin-1 targeted antibody) in combination with gemcitabine and Imprime PGG (beta 1,3/1,6 glucan) when given to patients with advanced and previously treated pancreatic ductal adenocarcinoma (PDAC).Up to 30 days post last dose
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Adverse EffectsCharacterize adverse effects (AE) of I-BTH-Gem in patients with advanced PDAC in the second and third line setting.Up to 30 days post final dose
Disease Response based on RECIST CriteriaEvaluate clinical response of I-BTH-Gem in patients with advanced PDAC in the second and third line setting (RECIST v 1.1).Up to 8 weeks following final dose.

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. Male or female ≥ 18 years 2. Histologically or cytologically confirmed adenocarcinoma of the pancreas, including pancreatic adenosquamous carcinoma, pancreatic anaplastic adenocarcinoma, pancreatic signet ring carcinoma, papillary mucinous carcinoma, acinar cell carcinoma, and ampulla of vater carcinoma,that is locally advanced (not able to proceed with surgery), recurrent, or metastatic (mixed adenocarcinoma of the pancreas is acceptable where the invasive component is predominantly adenocarcinoma) 3. Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1 4. Has an ECOG PS of 0, 1, or 2 5. Has been off chemotherapy for > or = 2 weeks 6. Has a patent biliary stent if required for biliary ductal obstruction, has adequate nutritional intake, and pain which is stable for a minimum of 24 hrs (pain score ≤ 3/10) 7. Has total bilirubin < 2 mg/dL, AST and ALT < 3.0 × ULN or < 5 x ULN for subjects with known hepatic metastases 8. Has serum creatinine < 2.5 × ULN 9. Has hemoglobin ≥ 9 g/dL, ANC ≥ 1.0 × 10^9/L, and platelet count ≥ 100 × 10^9/L 10. Must be willing and able to comply with study 11. Has read, understood and signed the ICF 12. Women of childbearing potential must not be pregnant or breast-feeding. In addition, a medically acceptable method of birth control must be used or total abstinence. Women who are postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) are not considered to be WOCP. 13. Men who are not surgically or medically sterile must agree to use an acceptable method of contraception. Male patients with female sexual partners who are pregnant, possibly pregnant, or who could become pregnant during the study must agree to use condoms at least 30 days after the last dose of study drug. Total abstinence is an acceptable alternative. 14. Prior systemic treatments for metastatic disease are permitted, including targeted therapies, biologic response modifiers, chemotherapy, hormonal therapy, or investigational therapy. 15. Availability of tissue if applicable (from the primary tumor or metastases)for banking 16. Willingness to donate blood for biomarker studies 17. Must have received at least one prior systemic chemotherapy on which disease progressed
    Exclusion Criteria:
    1. Has a diagnosis of resectable pancreatic adenocarcinoma 2. Had surgery within 4 weeks prior to study treatment 3. Has either untreated or symptomatic CNS mets 4. Has a known hypersensitivity to BTH1704, murine proteins, or any component of BTH1704 5. Has a known hypersensitivity to baker's yeast 6. Has had previous exposure to Imprime PGG 7. Has previously received an organ or progenitor/stem cell transplant 8. Has a history of blood clots, pulmonary embolism, or DVT unless controlled by anticoagulant treatment 9. Has a known history of HIV positivity or untreated & uncontrolled hepatitis B or C 10. Has any clinically significant infection 11. Has any other severe, uncontrolled medical condition, including uncontrolled DM or unstable CHF or has a known or suspected allergy to the study drug 12. Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormality that may increase the risk associated with study participation 13. Presence of any non-healing wound, fracture, or ulcer 14. Has any condition that, in the opinion of the investigator, might jeopardize the safety of the patient or interfere with protocol compliance 15. Has any mental or medical condition that prevents the patient from giving informed consent 16. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to gemcitabine or drugs to formulate.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

  • HiberCell, Inc.
  • PRINCIPAL_INVESTIGATOR: Neeta Venepalli, MD, University of Illinois at Chicago

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

NPCF Pop up

Make-A-Will Month

Snag 6508be92
Learn More
Donate Now Online
Other Ways to Donate